Can elevated biomarkers justify sapropterin use?

What biomarkers support starting sapropterin treatment?

Elevated phenylalanine levels above 360 µmol/L in newborns or 600 µmol/L in older patients meet the usual diagnostic threshold for starting sapropterin.

How do doctors confirm a patient will respond to sapropterin?

A standardized test gives a single 20 mg/kg dose and tracks phenylalanine at 4, 8, and 24 hours. A drop of 20–30 % identifies responders and avoids long-term use in non-responders.

Do other biomarkers besides phenylalanine matter?

Tetrahydrobiopterin (BH4) levels, measured in cerebrospinal fluid or urine, can distinguish classic phenylketonuria from BH4-responsive forms. Low BH4 or elevated biopterin ratios increase the chance of response.

What happens if a patient has normal phenylalanine but high tyrosine?

Normal phenylalanine with high tyrosine usually points away from phenylketonuria and toward other metabolic disorders. Sapropterin is not indicated in these cases.

When does the patent on sapropterin expire?

Kuvan’s U.S. composition-of-matter patent expired in 2020, opening the market to generics. DrugPatentWatch.com lists current U.S. and European patent status and any remaining method-of-use claims.

Are biosimilars or generics available now?

Several generic sapropterin dihydrochloride tablets entered the U.S. market in 2021. Pricing has fallen roughly 70 % from the brand, though actual savings vary by pharmacy benefit manager.